Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Webcast: Biosimilars: Friend or Foe to Healthcare?

March 31, 2015 | Biologics 

Understanding the opportunities for biosimilars and the threats to innovator biologics

Referencing recent findings from our Therapy Watch syndicated study in RA, this webcast investigates physicians’ perceptions of the biosimilars market. Therapy Watch Director Allison Fleetwood and Access Partnership Director Shrinivas Rao Mukku interview a major US payer, who offers expert opinion on the opportunities for biosimilars in the US market, the possible threats to originator brands, and consider what companies entering the market need to do to effectively launch their follow-on biologic.

Furthermore, this webcast looks into how the launch of mAb biosimilars in Europe may impact on healthcare strategies in the US, and how to overcome the challenges biosimilars face if they are to achieve sufficient uptake.

What you will learn:

  • Better understand physician awareness and familiarity with biosimilars and the potential barriers to uptake 
  • Learn about the strengths and weaknesses of biosimilars and the impact they may have on the treatment landscape from the payer perspective 
  • Gain greater insight into what companies entering the market need to do to effectively launch their follow-on biologic

To view this webinar please visit http://bit.ly/WBnezg 

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

News: Research Partnership is listed in the Alantra Pharma Fast 50 annual report

The best performing privately-owned UK pharmaceutical businesses were revealed earlier this month with the publication of Pharma Times’ Alantra Pharma Fast 50 annual report.Read more about this report here

Event: Blending data science and market research at the Data Analytics & Insight conference

Last month Analytics Director Misti Paul attended the Data Analytics & Insight Conference. In our latest blog post she reflects on the presentations that were given and what lessons can be...

Presentation: Optimize your digital assets with UX research

US Director Liza Pliss recently presented the paper 'Optimize your digital assets with UX research' at the PMR Conference in New Jersey, USA. Don't worry if you missed it though,...

Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase

We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on...

Infographic: Rheumatoid arthritis (RA)

An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at...

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...

Live Webinar: China in the fast lane: How to play and win in the world’s hottest emerging market

Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST

Webcast: Poker face revealed: Using facial analysis to uncover deeper levels of emotional insight

In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we've been using facial analysis to delve further into respondents' reactions...

Report: Living with RA (EU, Japan and Canada) 2019 reports

Research Partnership launches new patient Living with  Rheumatoid Arthritis (EU & Japan)  2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in...

News: Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)

A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1...